Trial Profile

Mechanism of Action and Clinical Effect of BI 655130 in Patients With Fistulizing Crohn's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spesolimab (Primary)
Indications Crohn's disease
Focus Pharmacodynamics; Pharmacogenomic
Acronyms BI 655130 treatment of fistulizing CD
Sponsors Boehringer Ingelheim

Most Recent Events

30 Jul 2022 This trial has been discontinued in Netherlands (Date of the global end of the trial : 04-Jul-2022), according to European Clinical Trials Database record.
28 Jul 2022 This trial has been discontinued in Denmark (End Date: 4 July 2022) according to European Clinical Trials Database record.
07 Jul 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com